292 related articles for article (PubMed ID: 22918042)
1. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor.
Zhou H; Li Z; Silver DL; Jiang XC
Biochim Biophys Acta; 2006 Dec; 1761(12):1482-8. PubMed ID: 17055779
[TBL] [Abstract][Full Text] [Related]
3. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
4. Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.
de Boer JF; Schonewille M; Boesjes M; Wolters H; Bloks VW; Bos T; van Dijk TH; Jurdzinski A; Boverhof R; Wolters JC; Kuivenhoven JA; van Deursen JM; Oude Elferink RPJ; Moschetta A; Kremoser C; Verkade HJ; Kuipers F; Groen AK
Gastroenterology; 2017 Apr; 152(5):1126-1138.e6. PubMed ID: 28065787
[TBL] [Abstract][Full Text] [Related]
5. LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight From Mouse Models.
Cedó L; Metso J; Santos D; García-León A; Plana N; Sabate-Soler S; Rotllan N; Rivas-Urbina A; Méndez-Lara KA; Tondo M; Girona J; Julve J; Pallarès V; Benitez-Amaro A; Llorente-Cortes V; Pérez A; Gómez-Coronado D; Ruotsalainen AK; Levonen AL; Sanchez-Quesada JL; Masana L; Kovanen PT; Jauhiainen M; Lee-Rueckert M; Blanco-Vaca F; Escolà-Gil JC
Circ Res; 2020 Aug; 127(6):778-792. PubMed ID: 32495699
[TBL] [Abstract][Full Text] [Related]
6. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
7. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.
Ma Y; Huang Y; Yan L; Gao M; Liu D
Pharm Res; 2013 May; 30(5):1447-57. PubMed ID: 23371517
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Genin MJ; Bueno AB; Agejas Francisco J; Manninen PR; Bocchinfuso WP; Montrose-Rafizadeh C; Cannady EA; Jones TM; Stille JR; Raddad E; Reidy C; Cox A; Michael MD; Michael LF
J Med Chem; 2015 Dec; 58(24):9768-72. PubMed ID: 26568144
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice.
Gautier T; de Haan W; Grober J; Ye D; Bahr MJ; Claudel T; Nijstad N; Van Berkel TJC; Havekes LM; Manns MP; Willems SM; Hogendoorn PCW; Lagrost L; Kuipers F; Van Eck M; Rensen PCN; Tietge UJF
J Lipid Res; 2013 Aug; 54(8):2195-2205. PubMed ID: 23620138
[TBL] [Abstract][Full Text] [Related]
10. Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates.
Amano Y; Shimada M; Miura S; Adachi R; Tozawa R
Eur J Pharmacol; 2014 Jan; 723():108-15. PubMed ID: 24361308
[TBL] [Abstract][Full Text] [Related]
11. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S
Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor.
de Aguiar Vallim TQ; Tarling EJ; Kim T; Civelek M; Baldán Á; Esau C; Edwards PA
Circ Res; 2013 Jun; 112(12):1602-12. PubMed ID: 23519696
[TBL] [Abstract][Full Text] [Related]
15. Antiatherosclerotic effect of farnesoid X receptor.
Mencarelli A; Renga B; Distrutti E; Fiorucci S
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
[TBL] [Abstract][Full Text] [Related]
16. Antidyslipidemic effects of a farnesoid X receptor antagonist in primates.
Amano Y; Shimada M; Miura S; Adachi R; Tozawa R
Life Sci; 2014 Jun; 106(1-2):25-31. PubMed ID: 24787893
[TBL] [Abstract][Full Text] [Related]
17. Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice.
Yakushiji E; Ayaori M; Nishida T; Shiotani K; Takiguchi S; Nakaya K; Uto-Kondo H; Ogura M; Sasaki M; Yogo M; Komatsu T; Lu R; Yokoyama S; Ikewaki K
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):591-7. PubMed ID: 26848156
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse.
Masson D; Staels B; Gautier T; Desrumaux C; Athias A; Le Guern N; Schneider M; Zak Z; Dumont L; Deckert V; Tall A; Jiang XC; Lagrost L
J Lipid Res; 2004 Mar; 45(3):543-50. PubMed ID: 14679166
[TBL] [Abstract][Full Text] [Related]
19. Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice.
Rocco DD; Okuda LS; Pinto RS; Ferreira FD; Kubo SK; Nakandakare ER; Quintão EC; Catanozi S; Passarelli M
Lipids; 2011 Jul; 46(7):617-25. PubMed ID: 21479674
[TBL] [Abstract][Full Text] [Related]
20. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
